Cryopreservation of siRNA-Treated Cells Is Feasible
Nucleic Acid Therapeutics · 2025-12 · 35 (6) · 280-285
DOI: 10.1177/21593337251381041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 23.12.2025. Verfasst von Melanie Sauer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tübingen, Germany. Hauptthemen laut MEDLINE: Cryopreservation, RNA, Small Interfering. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS.
Abstract (Originalsprache)
Cryopreservation is a routine step in the manufacturing process of adoptive cell therapies (ACT), providing critical logistic flexibility. RNA interference (RNAi)-based therapies are increasingly being explored as enhancers or modulators of ACT. However, the impact of cryopreservation on cells treated with RNAi-based therapies has not been investigated before. In this study, we addressed this knowledge gap by examining silencing efficacy in small interfering RNA (siRNA)-treated cells that undergo cryopreservation. Our findings demonstrate that silencing in cryopreserved cells is comparable to that in cells maintained continuously in culture. Moreover, we found that the duration of siRNA exposure plays a significant role in cells that later undergo cryopreservation, with extended exposure improving silencing efficiency. However, this effect diminishes at higher siRNA concentrations. Additionally, we showed that siRNA treatment is feasible at low temperatures (2°C–8°C), and siRNA-treated cells can be cryopreserved for extended periods (at least 1 month) without loss of efficacy. Our work establishes the feasibility of integrating siRNA treatments into current manufacturing processes for ACT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tübingen, Germany.
- Gene and RNA Therapy Center (GRTC), Faculty of Medicine, University Tuebingen, Tübingen, Germany.
- RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.
ORCID-Profile: Reka A Haraszti
Förderung
- NIH HHS
Zitieren
APA
Sauer, M., Segarra-Visent, X., Breuer, L., Tzirtziganis, V., Ryaykenen, T., Cooper, D. A., Echeverria, D., Kremer, A., & Haraszti, R. A. (2025). Cryopreservation of siRNA-Treated Cells Is Feasible. Nucleic Acid Therapeutics, 35(6), 280-285. https://doi.org/10.1177/21593337251381041
Vancouver
Sauer M, Segarra-Visent X, Breuer L, Tzirtziganis V, Ryaykenen T, Cooper DA, et al. Cryopreservation of siRNA-Treated Cells Is Feasible. Nucleic Acid Therapeutics. 2025;35(6):280-285. doi:10.1177/21593337251381041
BibTeX
@article{Sauer2025,
author = {Sauer, Melanie and Segarra-Visent, Xavier and Breuer, Leon and Tzirtziganis, Vasileios and Ryaykenen, Tatyana and Cooper, David A and Echeverria, Dimas and Kremer, Anastasia and Haraszti, Reka A},
title = {Cryopreservation of siRNA-Treated Cells Is Feasible},
journal = {Nucleic Acid Therapeutics},
year = {2025},
volume = {35},
number = {6},
pages = {280--285},
doi = {10.1177/21593337251381041}
}
EUVIMED